Marksans Pharma Ltd. benchmarking: Performance to industry peers

Financial

	Marksans Pharma	Viyash Scientific	Procter&Gamble Healt
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	25.0 .	n/a	n/a
Number of ANDA's Approved By USFDA	13.0 .	n/a	n/a
R&D as a % of Total Sales	3.0 %	0.0	n/a
Financials
5 yr Average ROE	17.57 %	4.43 %	36.03 %
5yr average Equity Multiplier	1.33	2.16	1.79
5yr Average Asset Turnover Ratio	0.9	0.95	0.77
5yr Avg Net Profit Margin	14.56 %	0.03 %	19.19 %
Price to Book	3.35	11.6	13.67
P/E	24.98	122.23	28.86
5yr Avg Cash Conversion Cycle	71.65 Days	49.09 Days	-155.74 Days
Inventory Days	89.77 Days	80.25 Days	36.01 Days
Days Receivable	65.99 Days	79.76 Days	40.92 Days
Days Payable	88.81 Days	114.46 Days	215.28 Days
5yr Average Interest Coverage Ratio	38.03	1.93	500.05
5yr Avg ROCE	21.95 %	6.67 %	30.21 %
5yr Avg Operating Profit Margin	20.32 %	7.74 %	27.53 %
5 yr average Debt to Equity	0.02	0.53	0.0
5yr CAGR Net Profit	10.03 %	-25.52 %	4.02 %
5yr Average Return on Assets	13.19 %	0.05 %	15.5 %
Shareholdings
Promoter Holding	43.87 %	61.31 %	51.82 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.02 %	8.52 %	0.0
Change in Mutual Fund Holding (3 Yrs)	3.8 %	6.19 %	2.86 %

	Marksans Pharma	Viyash Scientific	Procter&Gamble Healt
Product Wise Break-Up	Product Wise Break-Up Pain Management 44.0 Cough and colds 14.0 Cardiac Science 9.2 Gastro Intestinal 8.5 Central Nervous System (CNS) 8.1 Anti - Diabetes 1.6 Vitamins & Suppliments 0 Anti-Cancer 0 Anti-Hair Fall 0 Antibiotics 0 Anti-allergic 0 Miscellaneous 0 Active Pharmaceutical Ingredient 0 Formulations 0 Others 14.6	Product Wise Break-Up Cough and colds 0 Anti - Diabetes 0 Anti-Cancer 0 Pain Management 0 Anti-allergic 0 Formulations 56.23 Central Nervous System (CNS) 0 Active Pharmaceutical Ingredient (API) 42.77 Cardiac Science 0 Antibiotics 0 Vitamins & Suppliments 0 Anti-Hair Fall 0 Miscellaneous 0 Gastro Intestinal 0 Others 1.0	-
Location Wise Break-Up	Location Wise Break-Up North America 54.7 Europe 34.2 Australia 8.1 India 0 Turkey 0 LATAM 0 EM 0 Rest of the World 0 Asia 0 International 0 Domestic 0 Others 3.0	Location Wise Break-Up EM 0 India 0 Asia Pacific 28.68 Turkey 0 International 0 Domestic 0 North America 0 Australia 0 Rest of the World 26.19 LATAM 0 Europe 45.13	Location Wise Break-Up EM 0 India 0 Asia 0 Turkey 0 International 6.81 Domestic 93.19 North America 0 Australia 0 Rest of the World 0 LATAM 0 Europe 0
Customer Segment	Customer Segment OTC 78.8 Rx 21.2 Less regulated market 0 Regulated market 0	Customer Segment OTC 0 Regulated market 67.0 Rx 0 Less regulated market 33.0	-